Davendra Sohal, MD of Cleveland Clinic discusses Pancreatic Cancer News from ASCO GI 2016
Author: Editor
Davendra Sohal, MD of Cleveland Clinic discusses promise in MSI-High Colorectal Cancer at ASCO GI 2016
Davendra Sohal, MD of Cleveland Clinic discusses the highlights from ASCO GI 2016
Dr. Toshihiko Doi, MD of National Cancer Center Hospital East, Japan discusses Pembrolizumab more value in squamous cell carcinomas or adenocarcinomas at ASCO GI 2016
Dr. Toshihiko Doi, MD of National Cancer Center Hospital East, Japan discusses Pembrolizumab looks promising according to KEYNOTE-028 results at ASCO GI 2016
Dr. Toshihiko Doi, MD of National Cancer Center Hospital East, Japan discusses clinical trial efforts in UGI cancers with the anti-PD-1 and PD-L1 monoclonal antibodies at ASCO GI 2016
Dr. Dale Shepard, MD, PhD OF Cleveland Clinic discusses the next steps for checkpoint inhibitors after Checkmate-032 and KEYNOTE-028 trials in UGI malignancies at ASCO GI 2016
Dr. Dale Shepard, MD, PhD OF Cleveland Clinic discusses KEYNOTE-028 results with pembrolizuma at ASCO GI 2016
Dr. Dale Shepard, MD, PhD OF Cleveland Clinic discusses Checkmate-032 trial and the results presented in UGI cancers at ASCO GI 2016
Al B Benson, MD of Northwestern University explains TAS-102 at ASCO GI 2016
Al B Benson, MD of Northwestern University discusses the optimal dosage using Regorafinib in colorectal cancer at ASCO GI 2016
Al B Benson, MD of Northwestern University discusses managing patients on regorafenib including adverse events at ASCO GI 2016
Joel Randolph Hecht, MD of UCLA Health discusses T-DM1 trial results, surprising or disappointing? from ASCO GI 2016
Joel Randolph Hecht, MD of UCLA Health discusses phase II-III trial results T-DM1 in previously treated gastric and GE junction adenocarcinoma at ASCO GI 2016
Joel Randolph Hecht, MD of UCLA Health discusses how did the ToGA trial changed the management of HER2+ gastric carcinoma at ASCO GI 2016
Joel Randolph Hecht, MD of UCLA Health discusses FOLFOX + ziv-aflibercept placebo versus AVAGAST trial of capecitabine-cisplatin with or without bevacizumab at ASCO GI 2016
Joel Randolph Hecht, MD of UCLA Health discusses ASCO GI 2016: FOLFOX + ziv-aflibercept placebo adding anti-angiogenic agent to chemotherapy in advanced gastric and GE junction adenocarcinoma at ASCO GI 2016
Joel Randolph Hecht, MD of UCLA Health discusses antiangiogenic agents in advanced esophagogastric adenocarcinomas at ASCO GI 2016
Manish Shah, MD of Weill-Cornell Medical Center states that the future of gastric cancers will be targeted agents including immunotherapy at ASCO GI 2016
Manish Shah, MD of Weill-Cornell Medical Center discusses the standard of care for good performance status patients with advanced gastric adenocarcinomas at ASCO GI 2016
Manish Shah, MD of Weill-Cornell Medical Center discusses the phase II study of FOLFIRI versus FOLFOX7 in advanced gastric adenocarcinoma at ASCO GI 2016
Manish Shah, MD of Weill-Cornell Medical Center, NYC discusses FOLFIRI versus FOLFOX7 will this randomized trial advance the treatment paradigms for advanced gastric cancer at ASCO GI 2016
Manish Shah, MD of Weill-Cornell Medical Center, NYC answers the question does the Asian population differ from the western populations in regards to gastric cancers at ASCO GI 2016
What direction is research taking in the field of myeloproliferative neoplasms (MPNs)? Dr. Laura Michaelis of Medical College of Wisconsin supplies an overview of MPN therapies, both those currently in use and those still in development. Dr. Michaelis begins with JAK inhibitors and works her way through layers and iterations of newer, more innovative treatments, covering several new categories. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
On location in Orlando, Florida at the 2015 American Society of Hematology (ASH) conference, Andrew spends a few minutes with myeloma expert Dr. Stephen Nimer from the University of Miami Health System, discussing the role of epigenetics and immunotherapy as the newest line of defense against cancer. Dr. Nimer gives a short primer on epigenetics and then explains the biology behind its ability to re-educate cancer cells. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
At the 2015 National Cancer Research Institute (NCRI) Cancer Conference, Robert West, PhD, from University College London, London, UK, discusses data from monthly national surveys in adults in England on the use of electronic cigarettes (e-cigarettes) and its relationship with smoking uptake and smoking cessation. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 National Cancer Research Institute (NCRI) Cancer Conference, Sergio Quezada, PhD, from University College London, London, UK, discusses emerging immunotherapeutic approaches for treating various cancer types. The improved understanding of the underlying principles of cancer biology and immunology, including the mechanisms of checkpoint signalling pathways and actions of immunomodulators, have been an important advance in immunotherapeutic agent development. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Dr. William Wierda of MD Anderson Cancer Center shares his insights on the tornado of research activity out of ASH 2015 meeting (American Society of Hematology) and perspective on the latest news and research in the field of CLL. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
Patient Power founder, Andrew Schorr, caught up with CLL expert Dr. Thomas Kipps at the 2015 American Society of Hematology (ASH) meeting to hear his perspective on CLL news from the conference. Dr. Kipps is enthusiastic about the possible use of combination therapy: We might be able to truly affect a cure for this disease! Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
Dr. Michael Keating, from MD Anderson Cancer Center, joins us for another segment in our Ask The Expert series, answering a question about the potential combination of obinutuzamab (Gazyva) and ABT-199 (Venetoclax) and whether this is a treatment approach that could be effective and safe. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
Dr. Andrew Zelenetz of Memorial Sloan Kettering Cancer Center describes the expanding CLL and lymphoma armamentarium on location at the 2015 American Society of Hematology (ASH). Dr. Zelenetz and Carol Preston discuss the results of an international studydesigned to improve the current standard of carethat is now leading to a wealth of treatment choices. Says Dr. Zelenetz, We have the tools now to treat CLL in such a way that we can get deep remissions. Sponsored by the Patient Empowerment Network through educational grants from Teva and Pharmacyclics. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on…
CLL experts Drs. Zeev Estrov, Nicole Lamanna and Michael Keating at our town meeting at MD Anderson Cancer Center in Houston, Texas, discussed the various symptoms related to CLL. The physicians follow up the discussion answering the questions, How does CLL progress, and when should treatment begin? Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
On location in Orlando, Florida at the 2015 American Society of Hematology (ASH) annual meeting, MPN expert Dr. Claire Harrison, Hematologist at Guy and St. Thomas Hospital, covers the myeloproliferative neoplasm (MPN) highlights including drug and basic science research. Listen as she mentions key studies, both new for 2016 and ongoing with updated information. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
At the 2015 National Cancer Research Institute (NCRI) Cancer Conference, Elaine Vickers, PhD, Founder and Principal Trainer of Science Communicated, Sheffield, UK, discusses her workshops that aim to explain the scientific concepts, including the molecular and cellular basis of cancer and their clinical application, behind the plenary lectures at the conference. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Matthew Galsky, MD Director of Genitourinary Medical Oncology at the Tisch Cancer Institute discusses the role of neoadjuvant chemotherapy and the impact of the latest randomized trials in bladder cancer at ASCO GU 2016
Matthew Galsky, MD Director of Genitourinary Medical Oncology at the Tisch Cancer Institute discusses Immune checkpoint inhibitors in combination with chemotherapy or targeted agents for urothelial cancers at ASCO GU 2016
Matthew Galsky, MD Director of Genitourinary Medical Oncology at the Tisch Cancer Institute discusses Clinical trials in bladder cancer with Atezolizumab and Pembrolizumab at ASCO GU 2016
Matthew Galsky, MD Director of Genitourinary Medical Oncology at the Tisch Cancer Institute discusses Adjuvant radiation v. chemo-RT v. chemotherapy alone after radical cystectomy for locally advanced bladder cancer at ASCO GU 2016
Matthew Galsky, MD Director of Genitourinary Medical Oncology at the Tisch Cancer Institute discusses the Phase II trial of gemcitabine + cisplatin + ipilimumab in patients with metastatic urothelial cancer at ASCO GU 2016
Véronique Leblond, MD, PhD from the Hospital of Pitié Salpêtrière, Paris, France, provides an overview if the Phase III clinical trial of ibrutinib vs chlorambucil in chronic lymphocytic leukemia (CLL) patients over the age of 65. Progression free survival (PFS) and overall survival (OS) were increased in the ibrutinib arm, demonstrating the superior efficacy of this drug over chlorambucil.
Thomas J Kipps, MD from the University of California, San Diego, CA, discussed the current treatment landscape in chronic lymphocytic leukemia (CLL), considering the novel therapies being presented at the American Society of Hematology (ASH) 2015 Annual Meeting.
Thomas J Kipps, MD from the University of California, San Diego, CA, discussed the impact of the clinical trial of venetoclax (ABT-199) with obinutuzumab in the treatment landscape chronic lymphocytic leukemia (CLL).
Thomas J Kipps, MD from the University of California, San Diego, CA, provides an overview of the clinical trial RESONATE-2 comparing ibrutinib with chlorambucil in chronic lymphocytic leukemia (CLL) patients not suitable to receive standard chemotehrapy. Ibrutinib is a Bruton’s tyrosine kinase (BTK) inhibitor, that targets B-cells and causes them to leave the lymph nodes and bone marrow. This drug has been shown to be effective in the treatment of CLL and therefore it has been approved in relapsed disease as a single-agent. Patients in the ibrutinib arm had a longer progression free survival (PFS), and survival advantage over chlorambucil.
Martin JS Dyer, MA, DPhil, FRCP, FRCPath from the University of Leicester, Leicester, UK, provides an overview of a Phase I study of ONO/GS-4059, a selective Bruton’s tyrosine kinase (BTK) inhibitor, in relapsed and refractory mature B-cell malignancies. Prof. Dyer presents the data showing the reduced toxicity of ONO/GS-4059 in comparison with the 1st generation BTK inhibitor ibrutinib. Prof. Dyer also discusses
Peter Hillmen, MBChB, PhD from St. James’ University Hospital, Leeds, UK, discusses the importance of targeting proliferanting and quiescent chronic lymphocytic leukemia (CLL) cells. Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL.
At the American Society of Hematology (ASH) 2015 Annual Meeting, John Gribben, MD, DSc and Stephan Stilgenbauer, MD discuss the use of ibrutinib as front-line therapy in chronic lymphocytic leukemia (CLL).
At the American Society of Hematology (ASH) 2015 Annual Meeting, John Gribben, MD, DSc and Stephan Stilgenbauer, MD discuss the use of ibrutinib as front-line therapy in chronic lymphocytic leukemia (CLL).
At the American Society of Hematology (ASH) 2015 Annual Meeting, John Gribben, MD, DSc and Stephan Stilgenbauer, MD discuss the importance of Bcl-2-targeted therapies. They discuss recent sucesses of Bcl-2 targeting drugs, such as venetoclax (ABT-196) in the field of chronic lymphocytic leukemia.
At the American Society of Hematology (ASH) 2015 Annual Meeting, John Gribben, MD, DSc and Stephan Stilgenbauer, MD discuss the recent developments occuring in CLL and how certain molecules such as Bcl-2, BTK and PI3K, have moved from being biomarkers and stratification markers to becoming targets of the disease.
Barbara Eichhorst, MD from the Ludwig-Maximilians University, Munich, Germany, provides an overview of combination studies presented at the American Society of Hematology (ASH) 2015 Annual Meeting held in Orlando, FL. Dr Eichhorst gives an overview of the Phase III clinical trial comparing chlorambucil with ibrutinib as front-line therapies, and an overview of the Phase II clinical trial of venetoclax in chronic lymphocytic leukaemia (CLL) patients with 17p deletion.